Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$9.99M, compared with -$31.65M a year earlier. Trailing-twelve-month EBITDA was -$76.13M.
Context
- EBITDA amounted to 805.5% of revenue in FY2025, down 985.9 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of -$41.7M (+57.4%) for the fiscal year ending Dec 2026, a step up from the +22.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$9.99M+37.7% QoQ
- Last fiscal yearDec 2025
- -$97.79M+22.0% YoY
- LTMMar 2026
- -$76.13M+39.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +68.4% | +38.3% | -30.1 pp |
| 1 year | +22.0% | +57.4% | +35.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (97.79M) USD
- Year-over-year change
- +22.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (97.79M) | +22.0% |
| FY2024 | 2024-12-31 | (125.4M) | -3.9% |
| FY2023 | 2023-12-31 | (120.66M) | -5.7% |
| FY2022 | 2022-12-31 | (114.11M) | -3.0% |
| FY2021 | 2021-12-31 | (110.78M) | — |
EBITDA vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +39.6% is the 2nd highest of 11, against a peer median of +13.9%.
- EBITDA amounts to 455.3% of revenue for PRLD, versus a peer median of 773.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$45.49M USD | -75.7% | — | — |
| LTM Mar 2026 | -$46.56M USD | +46.6% | — | 67.3% | |
| LTM Mar 2026 | -$52.72M USD | +20.1% | — | 161.1% | |
| LTM Mar 2026 | -$58.85M USD | +7.0% | — | — | |
| LTM Mar 2026 | -$72.53M USD | +7.7% | — | 257.0% | |
| LTM Mar 2026 | -$75.47M USD | +22.0% | — | 33540.9% | |
| LTM Mar 2026 | -$75.93M USD | +0.5% | — | 547.9% | |
| LTM Mar 2026 | -$76.13M USD | +39.6% | — | 455.3% | |
| LTM Mar 2026 | -$84.35M USD | -214.9% | — | 142957.6% | |
| LTM Mar 2026 | -$111.97M USD | +23.4% | — | 999.5% | |
| FY2025 | -€128.15M EUR | +23.0% | — | 2858.6% | |
| Peer median (excluding PRLD) | — | +13.9% | — | 773.7% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7M | 12.14M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.71M |
| Gross Profit | 0 | 0 | 0 | 7M | 10.43M |
| Gross Margin | — | — | — | 100.0% | 85.9% |
| Research & Development | 86.78M | 92.89M | 103.39M | 118M | 94.3M |
| Selling, General & Admin | 26.96M | 30.65M | 28.88M | 28.72M | 22.41M |
| Operating Expenses | 113.74M | 123.54M | 132.28M | 146.71M | 115M |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.71M |
| EBITDA | (110.78M) | (114.11M) | (120.66M) | (125.4M) | (97.79M) |
| EBITDA Margin | — | — | — | -1791.4% | -805.5% |
| Operating Income | (113.74M) | (123.54M) | (132.28M) | (139.71M) | (104.57M) |
| Operating Margin | — | — | — | -1995.9% | -861.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.04M | 8.1M | 10.44M | 12.54M | 5.07M |
| Income Before Tax | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Pre-Tax Margin | — | — | — | -1816.8% | -819.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Net Margin | — | — | — | -1816.8% | -819.6% |
| EPS (Basic) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| EPS (Diluted) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| Weighted Avg Shares | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
| Weighted Avg Shares (Diluted) | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.